Class information for:
Level 1: OLAPARIB//SYNTHETIC LETHALITY//PARP INHIBITOR

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
16302 596 49.1 90%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
295 18105 FANCONI ANEMIA//ATAXIA TELANGIECTASIA//WERNER SYNDROME

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 OLAPARIB Author keyword 33 61% 6% 35
2 SYNTHETIC LETHALITY Author keyword 10 21% 7% 43
3 PARP INHIBITOR Author keyword 9 26% 5% 30
4 PARP INHIBITORS Author keyword 9 24% 5% 32
5 HOMOLOGOUS RECOMBINATION DEFICIENCY Author keyword 6 71% 1% 5
6 VELIPARIB Author keyword 6 50% 2% 9
7 EMSY Author keyword 6 53% 1% 8
8 BMN 673 Author keyword 6 100% 1% 4
9 CRUK GENE FUNCT Address 5 54% 1% 7
10 POLY ADP RIBOSE POLYMERASE INHIBITOR Author keyword 4 67% 1% 4

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 OLAPARIB 33 61% 6% 35 Search OLAPARIB Search OLAPARIB
2 SYNTHETIC LETHALITY 10 21% 7% 43 Search SYNTHETIC+LETHALITY Search SYNTHETIC+LETHALITY
3 PARP INHIBITOR 9 26% 5% 30 Search PARP+INHIBITOR Search PARP+INHIBITOR
4 PARP INHIBITORS 9 24% 5% 32 Search PARP+INHIBITORS Search PARP+INHIBITORS
5 HOMOLOGOUS RECOMBINATION DEFICIENCY 6 71% 1% 5 Search HOMOLOGOUS+RECOMBINATION+DEFICIENCY Search HOMOLOGOUS+RECOMBINATION+DEFICIENCY
6 VELIPARIB 6 50% 2% 9 Search VELIPARIB Search VELIPARIB
7 EMSY 6 53% 1% 8 Search EMSY Search EMSY
8 BMN 673 6 100% 1% 4 Search BMN+673 Search BMN+673
9 POLY ADP RIBOSE POLYMERASE INHIBITOR 4 67% 1% 4 Search POLY+ADP+RIBOSE+POLYMERASE+INHIBITOR Search POLY+ADP+RIBOSE+POLYMERASE+INHIBITOR
10 BRCANESS 3 43% 1% 6 Search BRCANESS Search BRCANESS

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MUTANT CELLS 25 36% 9% 55
2 OLAPARIB 15 56% 3% 18
3 BRCA MUTANT CELLS 13 53% 3% 17
4 PARP INHIBITORS 11 27% 6% 35
5 AZD2281 11 78% 1% 7
6 RIBOSE POLYMERASE INHIBITOR 7 48% 2% 11
7 PARP INHIBITOR 7 31% 3% 18
8 SYNTHETIC LETHALITY 6 22% 4% 26
9 BRCA MUTATION CARRIERS 6 30% 3% 17
10 POLYADP RIBOSE POLYMERASE INHIBITOR 5 22% 4% 22

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
An update on PARP inhibitors-moving to the adjuvant setting 2015 16 67 61%
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors 2015 11 71 55%
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies 2014 34 61 43%
The DNA damage response and cancer therapy 2012 250 67 34%
PARP inhibitors in ovarian cancer: Current status and future promise 2014 17 48 69%
An update on PARP inhibitors for the treatment of cancer 2015 2 56 48%
PARP inhibitors: A new era of targeted therapy 2015 2 26 42%
Searching for synthetic lethality in cancer 2011 45 41 44%
Applying Synthetic Lethality for the Selective Targeting of Cancer 2014 8 61 38%
Harnessing synthetic lethal interactions in anticancer drug discovery 2011 74 126 29%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 CRUK GENE FUNCT 5 54% 1.2% 7
2 TUMOUR PROFILING UNIT 3 57% 0.7% 4
3 CLIN TARGET VALIDAT 2 25% 1.0% 6
4 IMED ONCOL 1 50% 0.3% 2
5 MED ONCOLMED GYNECOL ONCOL PROGRAM 1 50% 0.3% 2
6 CANC UK GENE FUNCT REGULAT GRP 1 33% 0.5% 3
7 BASSER 1 40% 0.3% 2
8 PL DEV SUPPORT DIRECTORATE 1 21% 0.5% 3
9 BIOTECHNOL BUSINESS UNIT 1 50% 0.2% 1
10 CANC FEMME RECH CLIN 1 50% 0.2% 1

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000204778 POLYADP RIBOSE POLYMERASE//PARG//POLYADP RIBOSE GLYCOHYDROLASE
2 0.0000145131 BRCA1//BRCA2//HEREDITARY BREAST CANCER
3 0.0000124063 SYNTHETIC DOSAGE LETHALITY//YEAST DELETION//SYNTHETIC GENETIC ARRAY
4 0.0000094840 NIJMEGEN BREAKAGE SYNDROME//53BP1//NBS1
5 0.0000092660 ONCOTYPE DX//TRIPLE NEGATIVE BREAST CANCER//TRIPLE NEGATIVE
6 0.0000079696 OREGOVOMAB//AFLIBERCEPT//GI PERFORATION
7 0.0000078430 OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA
8 0.0000076859 QUIESCENT CELL//BORON TRACEDRUG//MILD TEMPERATURE HYPERTHERMIA
9 0.0000076078 RAD51//HOMOLOGOUS RECOMBINATION//RAD52
10 0.0000076016 CHK1//RAD9//CLASPIN